US 9,808,516 B2
Immunogenic fusion proteins for the treatment of cancer
Dirk G. Brockstedt, Richmond, CA (US); Charles G. Drake, Baltimore, MD (US); Marcella Fasso, Richmond, CA (US); Peter M. Lauer, Albany, CA (US); William G. Hanson, Walnut Creek, CA (US); Meredith Lai Ling Leong, Oakland, CA (US); and Christopher Steven Rae, Richmond, CA (US)
Assigned to Aduro Biotech, Inc., Berkeley, CA (US); and The Johns Hopkins University, Baltimore, MD (US)
Filed by Aduro Biotech, Inc., Berkeley, CA (US); and The Johns Hopkins University, Baltimore, MD (US)
Filed on Apr. 12, 2016, as Appl. No. 15/97,271.
Claims priority of provisional application 62/146,626, filed on Apr. 13, 2015.
Claims priority of provisional application 62/146,654, filed on Apr. 13, 2015.
Claims priority of provisional application 62/263,174, filed on Dec. 4, 2015.
Prior Publication US 2016/0324945 A1, Nov. 10, 2016
Int. Cl. A61K 39/00 (2006.01); C12N 9/12 (2006.01); C07K 14/47 (2006.01); C12N 9/16 (2006.01); C12N 9/48 (2006.01)
CPC A61K 39/0011 (2013.01) [C07K 14/4703 (2013.01); C12N 9/12 (2013.01); C12N 9/16 (2013.01); C12N 9/485 (2013.01); C12Y 207/10001 (2013.01); C12Y 301/03005 (2013.01); C12Y 304/17021 (2013.01); A61K 2039/523 (2013.01); C07K 2319/40 (2013.01)] 9 Claims
 
1. A recombinant Listeria monocytogenes host cell comprising a nucleic acid molecule encoding three separate fusion proteins, wherein the three separate fusion proteins are EGFRvIIIx5-SSX2, EGFRvIIIx5-PAP33-386, and EGFRvIIIx5-NKX3.1(R41G)11-234-PSMA1-20, 44-138, 169-750; and wherein:
a) EGFRvIIIx5-SSX2 is encoded by a nucleic acid sequence comprising the sequence set forth in SEQ ID NO:3;
b) EGFRvIIIx5-PAP33-386 is encoded by a nucleic acid sequence comprising the sequence set forth in SEQ ID NO:11; and
c) EGFRvIIIx5-NKX3.1(R41G)11-234-PSMA1-20, 44-138, 169-750 is encoded by a nucleic acid sequence comprising the sequence set forth in SEQ ID NO:15.